Wang Ying, Xiao Chun, Niu Hui, Li Jun, Rao Huimin, Li Ji'an
Second Department of Ophthalmology, The First People's Hospital of Aksu, Aksu, 843000, Xinjiang Autonomous Region, China.
Int Ophthalmol. 2025 Jan 24;45(1):32. doi: 10.1007/s10792-024-03402-4.
We aimed to evaluate the effects of autologous serum plus artificial tears on corneal sensation and tear film stability in patients with mild to moderate xerophthalmia after cataract surgery.
A total of 150 patients with mild to moderate xerophthalmia after one-time cataract surgery from March 2022 to September 2023 were selected and randomly divided into a control group (n = 75) and a study group (n = 75). The control group was treated with artificial tears (polyvinyl alcohol eye drops), while the study group was given autologous serum plus artificial tears. The treatment lasted for four weeks in both groups. The clinical efficacy was observed and adverse reactions were recorded.
The clinical effective rate of the study group was higher than that of the control group (96.00% versus 86.67%) (χ = 4.127, P < 0.05). After four weeks of treatment, the corneal sensation was superior to that before treatment in both groups, and it was better in the study group than that in the control group (Z = 2.053, P < 0.05). In comparison with the pre-treatment period, the tear film break-up time (BUT) increased, while the corneal fluorescein staining (FL) score and levels of inflammatory factors tumor necrosis factor-α, interleukin-6 (IL-6) and IL-1β dropped in both groups after treatment, and the study group had longer BUT and a lower FL score than those of the control group (t = 6.492, 7.033, 7.140, 4.709 and 3.059, P < 0.05). The incidence rates of adverse reactions were similar between the two groups (χ = 0.132, P > 0.05).
Autologous serum plus artificial tears can improve the corneal sensation and tear film stability and alleviate inflammatory responses without increasing adverse reactions in patients with mild to moderate xerophthalmia after cataract surgery.
我们旨在评估自体血清联合人工泪液对白内障术后轻至中度干眼症患者角膜感觉及泪膜稳定性的影响。
选取2022年3月至2023年9月行一次性白内障手术后出现轻至中度干眼症的150例患者，随机分为对照组（n = 75）和研究组（n = 75）。对照组使用人工泪液（聚乙烯醇滴眼液）治疗，研究组给予自体血清联合人工泪液治疗。两组治疗均持续4周。观察临床疗效并记录不良反应。
研究组临床有效率高于对照组（96.00% 对86.67%）（χ = 4.127，P < 0.05）。治疗4周后，两组角膜感觉均优于治疗前，且研究组优于对照组（Z = 2.053，P < 0.05）。与治疗前相比，两组治疗后泪膜破裂时间（BUT）延长，角膜荧光素染色（FL）评分及炎症因子肿瘤坏死因子-α、白细胞介素-6（IL-6）和白细胞介素-1β水平降低，且研究组BUT长于对照组，FL评分低于对照组（t = 6.492、7.033、7.140、4.709和3.059，P < 0.05）。两组不良反应发生率相似（χ = 0.132，P > 0.05）。
自体血清联合人工泪液可改善白内障术后轻至中度干眼症患者的角膜感觉和泪膜稳定性，减轻炎症反应，且不增加不良反应。
